Mantle Cell Lymphoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Mantle Cell Lymphoma - Pipeline Review, H2 2016

Mantle Cell Lymphoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Mantle Cell Lymphoma - Pipeline Review, H2 2016
Published Aug 10, 2016
426 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Mantle Cell Lymphoma - Pipeline Review, H2 2016, provides an overview of the Mantle Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline

  
Source:
Document ID
GMDHC8348IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents214
  List of Tables132
  List of Figures151
Introduction161
  Global Markets Direct Report Coverage161
Mantle Cell Lymphoma Overview171
Therapeutics Development182
  Pipeline Products for Mantle Cell Lymphoma Overview181
  Pipeline Products for Mantle Cell Lymphoma Comparative Analysis191
Mantle Cell Lymphoma Therapeutics under Development by Companies204
Mantle Cell Lymphoma Therapeutics under Investigation by Universities/Institutes241
Mantle Cell Lymphoma Pipeline Products Glance253
  Late Stage Products251
  Clinical Stage Products261
  Early Stage Products271
Mantle Cell Lymphoma Products under Development by Companies285
Mantle Cell Lymphoma Products under Investigation by Universities/Institutes331
Mantle Cell Lymphoma Companies Involved in Therapeutics Development3448
  AB Science SA341
  AbbVie Inc351
  Acetylon Pharmaceuticals, Inc.361
  Actinium Pharmaceuticals, Inc.371
  Affimed GmbH381
  Amgen Inc.391
  Asana BioSciences, LLC401
  Astellas Pharma Inc.411
  Astex Pharmaceuticals, Inc.421
  Bayer AG431
  BeiGene, Ltd.441
  Bristol-Myers Squibb Company451
  Celgene Corporation461
  Cellular Biomedicine Group, Inc.471
  Eisai Co., Ltd.481
  Eli Lilly and Company491
  EpiZyme, Inc.501
  Gilead Sciences, Inc.511
  GlaxoSmithKline Plc521
  Hutchison MediPharma Limited531
  ImmunoGen, Inc.541
  Immunomedics, Inc.551
  Incyte Corporation561
  Inflection Biosciences Limited571
  Johnson &Johnson581
  Juno Therapeutics Inc.591
  Karyopharm Therapeutics, Inc.601
  Kite Pharma, Inc.611
  LFB S.A.621
  MacroGenics, Inc.631
  MedImmune, LLC641
  Merck &Co., Inc.651
  Merck KGaA661
  Millennium Pharmaceuticals Inc671
  MorphoSys AG681
  Nordic Nanovector ASA691
  Novartis AG701
  Onconova Therapeutics, Inc.711
  Oncternal Therapeutics, Inc.721
  Patrys Limited731
  Pharmacyclics, Inc.741
  Portola Pharmaceuticals, Inc.751
  Seattle Genetics, Inc.761
  Selvita S.A.771
  Stemline Therapeutics, Inc.781
  Takeda Pharmaceutical Company Limited791
  TG Therapeutics, Inc.801
  Vivolux AB811
Mantle Cell Lymphoma Therapeutics Assessment8216
  Assessment by Monotherapy Products821
  Assessment by Combination Products831
  Assessment by Target845
  Assessment by Mechanism of Action895
  Assessment by Route of Administration942
  Assessment by Molecule Type962
Drug Profiles98314
  (INCB-039110 + INCB-040093) Drug Profile981
  13197 Drug Profile992
  AB-8779 Drug Profile1011
  abexinostat hydrochloride Drug Profile1023
  acalabrutinib Drug Profile1053
  ACY-241 Drug Profile1082
  ACY-775 Drug Profile1101
  AFM-11 Drug Profile1111
  alisertib Drug Profile1125
  AMG-319 Drug Profile1172
  ASN-002 Drug Profile1191
  AT-7519 Drug Profile1203
  avicin d Drug Profile1231
  BC-8Y90 Drug Profile1241
  bendamustine hydrochloride Drug Profile1253
  Betalutin Drug Profile1284
  BGB-3111 Drug Profile1322
  BLyS-gel Drug Profile1341
  BMS-986016 Drug Profile1352
  buparlisib hydrochloride Drug Profile1375
  carfilzomib Drug Profile14212
  CBM-C19.1 Drug Profile1541
  CBM-C20.1 Drug Profile1552
  Cellular Immunotherapy for Oncology Drug Profile1571
  Cellular Immunotherapy to Target CD19 for Oncology Drug Profile1581
  cerdulatinib Drug Profile1594
  copanlisib hydrochloride Drug Profile1634
  daratumumab Drug Profile16711
  denintuzumab mafodotin Drug Profile1783
  durvalumab Drug Profile18110
  E-7449 Drug Profile1911
  entospletinib Drug Profile1922
  epratuzumab Drug Profile1947
  EPZ-015666 Drug Profile2011
  HMPL-523 Drug Profile2022
  IBL-301 Drug Profile2042
  ibrutinib Drug Profile20625
  IGN-002 Drug Profile2312
  IMGN-529 Drug Profile2332
  IMMU-114 Drug Profile2352
  INA-01 Drug Profile2371
  INCB-40093 Drug Profile2381
  INCB-50465 Drug Profile2391
  inebilizumab Drug Profile2402
  inebilizumab + MEDI-0680 Drug Profile2421
  Iomab-B Drug Profile2435
  itacitinib adipate Drug Profile2483
  ixazomib citrate Drug Profile2519
  JCAR-014 Drug Profile2603
  JCAR-015 Drug Profile2635
  JCAR-017 Drug Profile2683
  JNJ-64052781 Drug Profile2712
  KTEC-19 Drug Profile2737
  LAM-002A Drug Profile2801
  M-7583 Drug Profile2811
  Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections Drug Profile2821
  Monoclonal Antibodies to Target ROR1 and CD3 for Oncology Drug Profile2831
  MOR-208 Drug Profile2845
  ON-123300 Drug Profile2891
  ONC-201 Drug Profile2904
  OSU-2S Drug Profile2941
  PATLM-1 Drug Profile2952
  PCAR-019 Drug Profile2971
  pembrolizumab Drug Profile29831
  ramucirumab Drug Profile32910
  ribociclib succinate Drug Profile3395
  S-055746 Drug Profile3441
  sapanisertib Drug Profile3453
  SEL-120 Drug Profile3482
  SEL-12034 Drug Profile3502
  SEL-24B489 Drug Profile3521
  selinexor Drug Profile35317
  SGN-CD70A Drug Profile3701
  SL-101 Drug Profile3711
  spebrutinib besylate Drug Profile3722
  TAK-659 Drug Profile3741
  TGR-1202 Drug Profile3757
  tisagenlecleucel-T Drug Profile3825
  tretinoin Drug Profile3871
  ublituximab Drug Profile3887
  UC-961 Drug Profile3952
  venetoclax Drug Profile3979
  VLX-1570 Drug Profile4062
  vorinostat Drug Profile4084
Mantle Cell Lymphoma Dormant Projects4123
Mantle Cell Lymphoma Discontinued Products4151
Mantle Cell Lymphoma Product Development Milestones4169
  Featured News &Press Releases4161
    Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Imbruvica4161
    Jun 06, 2016: MorphoSys Presents Updated Clinical Data for MOR208 in Non-Hodgkins Lymphoma at ASCO 20164161
    Jun 06, 2016: Nature publication on the anti-cancer mode-of-action of VLX15704171
    May 02, 2016: Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications4181
    Apr 13, 2016: TG Therapeutics Announces Issuance of Composition of Matter Patent for TG-1101 in the United States4181
    Mar 09, 2016: Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen4191
    Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications4191
    Dec 24, 2015: SymBio Files Supplemental NDA for TREAKISYM in a 25mg Vial (Different Strength)4201
    Dec 24, 2015: SymBio Files Supplemental NDA for TREAKISYM in First-Line Low-grade NHL and MCL4201
    Dec 07, 2015: Imbruvica (Ibrutinib) Phase 3 Ray Data Show Significant Reductions in Disease Progression Versus Temsirolimus in Relapsed/Refractory Mantle Cell Lymphoma Patients4201
    Dec 07, 2015: TG Therapeutics Announces Oral Presentation of Novel Pre-Clinical Combinations With TGR-1202 by Investigators at Columbia University at the 57th American Society of Hematology Annual Meeting4211
    Dec 07, 2015: TG Therapeutics Announces Data Presentation for TG-1101 in Combination With Ibrutinib at the 57th American Society of Hematology Annual Meeting4221
    Nov 30, 2015: New Data from Bayer s Portfolio in Oncology to be Presented at ASH 20154231
    Nov 19, 2015: The Mayo Clinic publishes new data on Vivolux drug candidate VLX 1570 in Ibrutinib-Resistant Mantle Cell Lymphoma at the ash 57th annual conference, Orlando, Florida4231
    Nov 09, 2015: Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 in Patients With Relapsed or Refractory Mantle Cell Lymphoma to Support Registration for a Second Indication4241
Appendix4252
  Methodology4251
  Coverage4251
  Secondary Research4251
  Primary Research4251
  Expert Panel Validation4251
  Contact Us4251
  Disclaimer4261

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Mantle Cell Lymphoma - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mantle-Cell-Lymphoma-Pipeline-Review-H2-2016-2088-16356>
  
APA:
Global Markets Direct - Market Research. (2016). Mantle Cell Lymphoma - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mantle-Cell-Lymphoma-Pipeline-Review-H2-2016-2088-16356>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.